Literature DB >> 24355634

Pulmonary hypertension due to left heart diseases.

Jean-Luc Vachiéry1, Yochai Adir2, Joan Albert Barberà3, Hunter Champion4, John Gerard Coghlan5, Vincent Cottin6, Teresa De Marco7, Nazzareno Galiè8, Stefano Ghio9, J Simon R Gibbs10, Fernando Martinez11, Marc Semigran12, Gerald Simonneau13, Athol Wells14, Werner Seeger15.   

Abstract

Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-LHD is unknown, a subset of patients might present significant PH that cannot be explained by a passive increase in left-sided filling pressures. The term "out-of-proportion" PH has been used to identify that population without a clear definition, which has been found less than ideal and created confusion. We propose a change in terminology and a new definition of PH due to LHD. We suggest to abandon "out-of-proportion" PH and to distinguish "isolated post-capillary PH" from "post-capillary PH with a pre-capillary component" on the basis of the pressure difference between diastolic pulmonary artery pressure and pulmonary artery wedge pressure. Although there is no validated treatment for PH-LHD, we provide insights into management and discuss completed and randomized trials in this condition. Finally, we provide recommendations for future clinical trials to establish safety and efficacy of novel compounds to target this area of unmet medical need.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CO; Cpc-PH; DPD; EF; HF; HF-pEF; LHD; LV; NO; PAH; PAWP; PCWP; PDE5; PH; PVD; PVR; RCT; RHC; RV; SV; TPG; VO(2); cardiac output; clinical trials; combined post-capillary and pre-capillary PH; diastolic pressure difference; ejection fraction; heart failure; heart failure with preserved ejection fraction; left heart disease; left ventricle/ventricular; mPAP; mean pulmonary artery pressure; nitric oxide; oxygen consumption; phosphodiesterase type 5; pulmonary arterial hypertension; pulmonary artery wedge pressure; pulmonary capillary wedge pressure; pulmonary hypertension; pulmonary vascular disease; pulmonary vascular resistance; randomized controlled trial; right heart catheterization; right ventricle; sGC; soluble guanylate cyclase; stroke volume; transpulmonary gradient

Mesh:

Year:  2013        PMID: 24355634     DOI: 10.1016/j.jacc.2013.10.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  174 in total

1.  Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease.

Authors:  Kim-Lien Nguyen; Xin Tian; Shoaib Alam; Alem Mehari; Steve W Leung; Catherine Seamon; Darlene Allen; Caterina P Minniti; Vandana Sachdev; Andrew E Arai; Gregory J Kato
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

Review 2.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 3.  Pulmonary Hypertension with Valvular Heart Disease: When to Treat the Valve Disease and When to Treat the Pulmonary Hypertension.

Authors:  Christophe Martinez; Toshimitsu Tsugu; Tadafumi Sugimoto; Patrizio Lancellotti
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

4.  Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos Santos-Gallego; Kenneth Fish; Nadjib Hammoudi; Antoine Chaanine; Samantha Torquato; Charbel Naim; Borja Ibanez; Daniel Pereda; Ana García-Alvarez; Valentin Fuster; Partho P Sengupta; Jane A Leopold; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-22       Impact factor: 4.733

Review 5.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

6.  Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction.

Authors:  Julien Magne; Dania Mohty; Alessandro Piccardo; Cyrille Boulogne; Mathieu Deltreuil; Vincent Petitalot; Najmeddine Echahidi; Nicole Darodes; Patrice Virot; Thibaud Damy; Victor Aboyans
Journal:  Clin Res Cardiol       Date:  2017-02-14       Impact factor: 5.460

7.  Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression.

Authors:  Huan Wang; Lei Hou; Dongmin Kwak; John Fassett; Xin Xu; Angela Chen; Wei Chen; Bruce R Blazar; Yawei Xu; Jennifer L Hall; Jun-Bo Ge; Robert J Bache; Yingjie Chen
Journal:  Hypertension       Date:  2016-05-09       Impact factor: 10.190

8.  Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.

Authors:  Nadine Al-Naamani; Ioana R Preston; Jessica K Paulus; Nicholas S Hill; Kari E Roberts
Journal:  JACC Heart Fail       Date:  2015-06       Impact factor: 12.035

9.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

10.  Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Authors:  Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain
Journal:  Chest       Date:  2018-08-24       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.